# THOMAS PATRICK AHERN CURRICULUM VITAE

Position: Assistant Professor

Department of Surgery

Address: 89 Beaumont Avenue

Given Building, Room D317A

Department of Surgery

The Robert Larner, M.D. College of Medicine

University of Vermont Burlington, VT 05405 Voice: (802) 656-3690

email: thomas.ahern@med.uvm.edu

website: http://med.uvm.edu/surgery/bio?BioID=25374

#### **EDUCATION**

<u>Year</u>	<u>Instituition</u>	<u>Degree</u>	Area of Degree,
			<b>Accolades</b>
2012	Harvard School of Public Health	Post-Doctoral	Cancer Epidemiology
2010	Boston University	Ph.D.	Epidemiology
2006	Boston University	M.P.H	Epidemiology
1999	University of Vermont	B.S.	Biochemistry

#### LICENSES, CERTIFICATION

Years License/Certification

#### **FACULTY POSITIONS HELD**

<b>Years</b>	<b>Institution</b>	<b>Academic Title</b>	<b>Department</b>
2013-Present	University of Vermont,	Assistant	Surgery
	Larner College of Medicine	Professor	
2012-2013	Brigham and Women's Hospital	Associate	Medicine
		Epidemiologist	
2011-2012	Harvard Medical School	Instructor	Medicine

#### OTHER POSITIONS AND MAJOR ADMINISTRATIVE POSITIONS HELD

<u>Years</u>	<u>Location/Program Name</u>	<u>Role</u>
2012-2013	Department of Clinical Epidemiology, Aarhus	Visiting Fellow
	University, Denmark	

6/7/2018	Thomas Patrick Ahern
Year	Name of Award
2011	Fred F. Kadlubar Scholar-in-Training Award
	<ul> <li>American Association for Cancer Research</li> </ul>
2011	Best Presentation by a Postdoctoral Fellow
	Harvard School of Public Health
2012	Molecular Epidemiology Group Scholar-in-Training Award
	American Association for Cancer Research
2012, 2014,	Loan Repayment Program, Clinical Research
2015, 2011,	National Institutes of Health
2017	James E. Demeules Award for Dedication to Excellence in Research
2017	
2010	• Department of Surgery, University of Vermont Medical Center
2018	Rising Star New Investigator Award
	• Dean's Excellence in Research Awards, The Robert Larner,
	M.D. College of Medicine at The University of Vermont
LEVINODDC/AD	TEAC OF INTERPRET
	REAS OF INTEREST
1 0,	lecular Epidemiology; Pharmacoepidemiology; Breast Neoplasms; Medical
Oncology	
	DESCRIPTION OF THE PARTY OF THE
	PROFESSIONAL ACTIVITIES- OVERALL [optional-needed for
	ppointment] Principle activity (e.g. teaching, research or clinical) [Focus on
•	years, but include longer time periods as appropriate. Be concise and limit to
500 words or less.	
TBD	
	A COOMBI ICHMENTEO DI
	ACCOMPLISHMENTS Please indicate no more than 8 career
accomplishments.	Use Single sentences and bullets
TBD	
וטט	

#### PROFESSIONAL SERVICE

DEPARTMENTAL SERVICE

YearsDepartmentCommitteeRole2010-2012Channing Division ofChanning HappinessMember

Network Medicine,

Brigham and

Women's Hospital and Harvard Medical

School

2014-Present Surgery Surgical Senior Member

Program Committee

2015-Present Surgery Surgical Research Member

Committee

Committee

#### **COLLEGE SERVICES**

Years Service Committee Role

Vermont Cancer Center Research Symposium Co-chair

Symposium Planning Committee (with Professor Chip Cole)

2016-Present Data Stewardship Committee, Member

Vermont Health Care Uniform Reporting and Evaluation System

(VHCURES)

#### MEDICAL CENTER SERVICE

Years Service Committee Role

#### UNIVERSITY SERVICE

Years Service Committee Role

2016-Present University of Vermont Faculty Senate Elected Senator

**GOVERNMENT** 

Years Service Committee Role

#### SOCIETY MEMBERSHIPS

Years Society

2006-Present Society for Epidemiologic Research

2009-Present American Association for Cancer Research 2016-Present International Society for Pharmacoepidemiology

#### SERVICE TO PROFESSIONAL ORGANIZATIONS

<b>Years</b>	Service Committee	Role
2014	Abstract Mentoring Committee,	Mentor
	Society for Epidemiologic Research	
2014-2015	Post-Doctoral Grant Review Committee,	Reviewer
	Susan G. Komen for the Cure	
2014	Session Co-chair, Annual Meeting of	Co-chair
	the Society for Epidemiologic Research,	
	"Modifiable risk factors for breast	
	cancer: still searching"	
2015	Grant Review Committee,	Reviewer
	Mary Kay Ash Charitable Foundation	
2015-2018	Awards Committee,	Member
	Society for Epidemiologic Research	
2016-Present	Abstract Review Committee,	Member
	Society for Epidemiologic Research	
2018-Present	Awards Committee,	Co-chair
	Society for Epidemiologic Research	
2018	Abstract Review Committee,	Member
	International Society for	
	Pharmacoepidemiology	

# SERVICE TO PROFESSIONAL PUBLICATIONS

Years	Journal/Publication/Board
Multiple,	JAMA Oncology, <i>Ad hoc</i> reviewer.
ongoing	Journal of the National Cancer Institute, Ad hoc reviewer.
	Journal of Clinical Oncology, <i>Ad hoc</i> reviewer.
	British Medical Journal, <i>Ad hoc</i> reviewer.
	Epidemiology, Ad hoc reviewer.
	American Journal of Epidemiology, <i>Ad hoc</i> reviewer.
	Cancer Causes and Control, Ad hoc reviewer.
	The Oncologist, <i>Ad hoc</i> reviewer.
	Pharmacoepidemiology and Drug Safety, Ad hoc reviewer.
	British Journal of Cancer, Ad hoc reviewer.
	Canadian Medical Association Journal, <i>Ad hoc</i> reviewer.
	European Journal of Cancer, Ad hoc reviewer.
	European Journal of Epidemiology, <i>Ad hoc</i> reviewer.
	The Breast, Ad hoc reviewer.
	Preventive Medicine, <i>Ad hoc</i> reviewer.
	Journal of Clinical Epidemiology, <i>Ad hoc</i> reviewer.
	Clinical Epidemiology, <i>Ad hoc</i> reviewer.
	Pediatrics, <i>Ad hoc</i> reviewer.
	Breast Cancer Research and Treatment, Ad hoc reviewer.

# PUBLIC SERVICE

Years	Service Role
1995-2000	Emergency Medical Technician, University of Vermont Rescue Squad

## **SUMMARY OF SERVICE ACTIVITIES**

#### **TEACHING**

## FORMAL SCHEDULED CLASSES

Year	Course Title	Cou R	rse E	Hours	Number of Learners	Level
2012, 2014, 2016, 2018	Analysis, validity, and inference in observational epidemiology, University of Tampere, Finland		X	8 hrs/day 5 days	~20	G

## CURRICULUM DEVELOPMENT

## POSTGRADUATE AND OTHER COURSES

<b>Years</b>	Department	Responsibility
2016-2018	"Introduction to Clinical Research"	Course faculty;
	Offered to UVM Medical Group physicians.	responsible for didactic
	Provides instruction in basic study design and	lectures and
	analysis. Facilitates individual research projects	mentoring/analytic
	using secondary data from the Jeffords Institute for	support for student
	Quality.	projects

#### PREDOCTORAL STUDENTS SUPERVISED OR MENTORED

Dates	Name	Program School	Role	<b>Current Position</b>
2012	Gitte Vrelits Sørensen, Medical student	Aarhus University	Research year advisor	Attending physician
2015	Rose Leshner, Undergraduate	Honors College University of Vermont	Thesis advisor	Yoga instructor
2016	Simon Ramsdal Sørensen, Medical student	Aarhus University	Research year advisor	Medical student

## DISSERTATION/THESIS COMMITTEE MEMBERSHIP

Dates	Name	Program	Role	Current
		School		Position
2016-	Anne Broe	Clinical Biochemistry and	Doctoral thesis	Doctoral student
present		Pharmacology,	committee	
		University of Southern	member	
		Denmark		
2016-	Zandra Nymand Ennis	Clinical Biochemistry and	Doctoral thesis	Doctoral student
present		Pharmacology,	committee	

6/7/2018				atrick Ahern
		University of Southern	member	
		Denmark		
2017	E. Ross Colgate	Clinical and Translational	Doctoral thesis	Faculty Scientist,
		Science,	committee	University of

member

#### POSTDOCTORAL FELLOWS AND RESIDENTS DIRECTLY SUPERVISED OR MENTORED

University of Vermont

Dates	Name	Fellow	Faculty Role	<b>Current Position</b>
		Mayo Fujii		

## **INFORMAL TEACHING**

Year	One Sentence Description of Information Teaching
2016-present	Deliver an annual series of didactic lectures to resident physicians in surgery
	covering topics in biostatistics and critical appraisal of clinical research

#### **FACULTY MENTORED**

Dates	Name	Position while Mentored	Faculty Role	<b>Current Position</b>

#### OTHER VISITING FACULTY SUPERVISED

Years	Names	University/College

#### **TEACHING AIDS**

#### TEACHING AWARDS AND NOMINATIONS

Year Award

*Teaching portfolio available on request or attached (if appropriate)* 

#### SUMMARY OF TEACHING ACTIVITIES

#### RESEARCH AND SCHOLARLY ACTIVITIES

#### RESEARCH AWARDS AND GRANTS

#### **Ongoing Research Support**

R03 ES027933

PI: Ahern, TP

2017-2019

Vermont

Predicting phthalate bio-burden through medication and dietary supplement exposure The major goals of this project are (1) develop a model to predict phthalate bio-burden based on intake of prescription medications and dietary supplements; and (2) apply the model to multiply impute phthalate exposure in a large U.S. cohort study in order to measure the association between phthalate exposure and breast cancer risk.

Role: PI

P20 GM103644 PI: Higgins/Kurti

2017-2018

Vermont Center on Behavior and Health

The goal of the Center is to investigate the relationships between personal behavior patterns (e.g., substance abuse, sedentary lifestyle, medication non-adherence) and risk for chronic disease and premature death. The overarching focus is on developing and evaluating clinical interventions for these risk behaviors and examining biases in decision-making and other potential mechanisms underpinning vulnerability to unhealthy behavior patterns using a behavioral economic conceptual framework. Dr. Ahern is a Project Director in the Center, leading a study of the impact of behavioral factors on mammographic breast density and cancer-associated microRNAs in a high-risk population.

Role: Project Director

584644 PI: Ahern 2018-2019

St. Baldrick's Foundation

Life-course phthalate exposure and pediatric cancer incidence

Research grant to support a Danish nationwide cohort study of *in utero* and early life phthalate exposure through pharmaceutical products in relation to incidence of pediatric malignancy.

## **Completed Research Support**

RO1 CA166825 PI: Lash, TL 2016-2018

New and integrated perspectives on modification of tamoxifen effectiveness

The major goals of this project are to elucidate the impact of genetic and pharmacological impairment of enzymes in the tamoxifen metabolic pathway on recurrence risk in premenopausal women with ER-positive breast cancer who are treated with tamoxifen.

Role: Co-Investigator

CCR13264024 PI: Ahern 2014-2018

Susan G. Komen for the Cure

Breast cancer risk in chronic users of phthalate-containing medications

Career Catalyst Award to support salary and career development, centered on the conduct of a population-based pharmacoepidemiologic study of phthalate excipients and breast cancer risk.

(No number issued) PI: Ahern 2014-2015

Lake Champlain Cancer Research Organization Pilot Grant

GATA3 Binding Profiles in Archival Breast Tumors: ChIP-Seq Method Refinement and Validity Assessment

Support development of chromatin immunoprecipitation/massively parallel sequencing (ChIP-Seq) protocol for use in formalin-fixed, paraffin-embedded archival breast tumors.

003-14 PI: Ahern 2014-2015

Mary Kay Ash Charitable Foundation

Research grant to support an investigation of host and breast tumor biomarkers that may predict response to adjuvant therapy with simvastatin.

BC073012 PI: Ahern 2008-2011

Congressionally Directed Medical Research Programs/Breast Cancer Research Program Modification of tamoxifen effectiveness by gene polymorphisms, regulatory proteins,

and other drugs

Training award to support full-time on dissertation studies and related research activities.

#### **Pending**

R01 LM013049 PI: Lash

Improving Reproducibility by Incorporating Uncertainty

The goal of this project is to build a novel informatics platform to improve the reproducibility of epidemiologic studies in contentious topic areas with apparently heterogeneous evidence bases. We hypothesize that reproducibility and scientific consensus building will be enhanced by quantitative correction for systematic biases affecting individual studies, followed by meta-analysis incorporating prior information.

2019-2023

Role: Co-Investigator

#### **Selected Unfunded Grant Submissions**

R21 CA223989 Role: PI Submitted: 2/2017 Score: Not discussed Discovering molecular pathways in breast tumor response to statin treatment The goal of this application was to study the molecular pathways that mediate the well-documented anti-proliferative effect of statins in breast tumors. The application was not discussed at study section, but was submitted as a new R01 in June 2018.

R21 CA223308 PI: Wood, ME Submitted: 10/2017 Score: 31 (17%) Validation and functional significance of a novel miRNA signature predictive of long-term risk of breast cancer

The goal of this application was validate and refine a biosignature of breast cancer risk developed in the High Risk Breast Program Cohort at the UVM Medical Center.

Role: Co-PI

#### **SCHOLARSHIP**

#### **Peer Reviewed Publications**

#### Original Research

- 1. Bednar MM, Gross CE, Russell SR, Fuller SP, **Ahern TP,** Howard DB, Falck JR, Reddy KM, Balazy, M. 16(R)-hydroxyeicosatertraenoic acid, a novel cytochrome P450 product of arachnidonic acid, suppresses activation of human polymorphonuclear leukocyte and reduces intracranial pressure in a rabbit model of thromboembolic stroke. Neurosurgery 2000:47:1410-18:discussion 1418-9.
- 2. **Ahern TP**, Larsson H, Garne JP, Cronin-Fenton DP, Sorensen HT, Lash TL. Trends in breast-conserving surgery in Denmark, 1982-2002. Eur J Epidemiol 2008;23:109-14.
- 3. **Ahern TP**, Lash TL, Sorensen HT, Pedersen L. Digoxin treatment is associated with an increased incidence of breast cancer: a population-based case-control study. Breast Cancer Res 2008;10:R102. PMCID: PMC2656898.
- 4. Lash TL, Pedersen L, Cronin-Fenton D, **Ahern TP**, Rosenberg CL, Lunetta KL, Silliman RA, Hamilton-Dutoit S, Garne JP, Ewertz M, Sørensen HT. Tamoxifen's protection against breast cancer recurrence is not reduced by concurrent use of the SSRI citalopram. Br J Cancer 2008;99:616-21. PMCID: PMC2527838.
- 5. **Ahern TP**, Lash TL, Thwin SS, Silliman RA. Impact of acquired comorbidities on all-cause mortality rates among older breast cancer survivors. Med Care 2009;47:73-9. PMCID: PMC2933563.

Thomas Patrick Ahern

6. **Ahern TP**, Lash TL, Egan KM, Baron JA. Lifetime tobacco smoke exposure and breast cancer incidence. Cancer Causes Control 2009;20:1837-44.

- 7. **Ahern TP**, Bosco JLF, Silliman RA, et al. Potential misinterpretations caused by collapsing upper categories of comorbidity indices: an illustration from a cohort of older breast cancer survivors. Clinical Epidemiology 2009;1:93-100. PMCID: PMC2943165.
- 8. **Ahern TP**, Pedersen L, Cronin-Fenton DP, Sorensen HT, Lash TL. No increase in cancer recurrence with concurrent use of tamoxifen and some CYP2D6-inhibiting medications. Cancer Epidemiol Biomarkers Prev 2009;18:2562-4. PMCID: PMC2742564.
- 9. Lee JC, **Ahern TP**, Chaves FP, Quillen K. Utility of hematologic and volume, conductivity, and scatter parameters from umbilical cord blood in predicting chorioamnionitis. Int J Lab Hematol 2009;32:351-9.
- 10. Lash TL, Cronin-Fenton D, **Ahern TP**, Rosenberg CL, Lunetta KL, Silliman RA, Hamilton Dutoit S, Garne JP, Ewertz M, Søresen HT, Pedersen L. Breast cancer recurrence risk related to concurrent use of SSRI antidepressants and tamoxifen. Acta Oncol 2010;49:305-12. PMCID: PMC2892037.
- 11. **Ahern TP**, Christensen M, Cronin-Fenton DP, Lunetta KL, Rosenberg CL, Sørensen HT, Lash TL, Hamilton-Dutoit S. Concordance of metabolic enzyme genotypes assayed from paraffin-embedded, formalin-fixed breast tumors and normal lymphatic tissue. Clinical Epidemiology 2010;2:241-6. PMCID: PMC2998813.
- 12. Lash TL, Cronin-Fenton DP, **Ahern TP**, et al. CYP2D6 inhibition and breast cancer recurrence in a Danish population-based study. J Natl Cancer Inst 2011;103:489-500. PMCID: PMC3057982.
- 13. **Ahern TP,** Pedersen L, Tarp M, Cronin-Fenton DP, Garne JP, Silliman RA, Sørensen HT, Lash TL. Statin prescriptions and breast cancer recurrence risk: A Danish nationwide prospective cohort study. J Natl Cancer Inst 2011;103:1461-8. PMCID: PMC3186780.
- 14. **Ahern TP,** Pedersen L, Svaerke C, Rothman KJ, Sørensen HT, Lash TL. The association between vitamin K antagonist therapy and site-specific cancer incidence, estimated by using heart valve replacement as an instrumental variable. Am J Epidemiol 2011;174:1382-90. PMCID: PMC3276295.
- 15. **Ahern TP,** Christensen M, Cronin-Fenton DP, Lunetta KL, Søiland H, Gjerde J, Garne JP, Rosenberg CL, Silliman RA, Sørensen HT, Lash TL, Hamilton-Dutoit S. Functional polymorphisms in UDP-glucuronosyl transferases and recurrence in tamoxifen-treated breast cancer survivors. Cancer Epidemiol Biomarkers Prev 2011;20:1937-43. PMCID: PMC3169710.
- 16. Cronin-Fenton DP, Hellberg Y, Lauridsen KL, Ahern TP, Garne JP, Rosenberg CL, Silliman RA, Sørensen HT, Lash TL, Hamilton-Dutoit S. Factors associated with concordant estrogen receptor expression at diagnosis and centralized re-assay in a Danish population-based breast cancer study. Acta Oncologica. 2012;51:254-61. PMCID: PMC3264781.
- 17. Lash TL, **Ahern TP**. Bias Analysis to Guide New Data Collection. Int J Biostat 2012;8:4679.
- 18. Sørensen GV, Ganz PA, Cole SW, Pedersen L, Sørensen HT, Cronin-Fenton D, Garne JP, Christiansen P, Lash TL, Ahern TP. Use of beta blockers, ACE inhibitors, angiotensin II receptor blockers and risk of breast cancer recurrence: A Danish nationwide prospective cohort study. J Clin Oncol. 2013;31:2265-72. PMCID: PMC3677839.

19. **Ahern TP**, Hankinson SE, Willett WC, Pollak MN, Eliassen AH, Tamimi RM. Plasma c-peptide, mammographic breast density, and risk of invasive breast cancer. Cancer Epidemiol Biomarkers Prev. 2013;22:1786-96. PMCID: PMC3809910.

- 20. Cronin-Fenton DP, Christensen M, Lash TL, **Ahern TP**, Pedersen L, Garne JP, Ewertz M, Autrup H, Sørensen HT, Hamilton-Dutoit S. Manganese superoxide dismutase and breast cancer recurrence: A Danish clinical registry-based case-control study, and a meta-analysis. PLoS ONE. 2014;9:e87450. PMCID: PMC3909115.
- 21. **Ahern TP**, Tamimi RM, Rosner BA, Hankinson SE. Digoxin use and risk of invasive breast cancer: evidence from the Nurses' Health Study and meta-analysis. Breast Cancer Res Treat. 2014;144(2):427-35. PMCID: PMC4010120.
- Lietzen LW, Ahern TP, Christiansen PM, Jensen AB, Sørensen HT, Lash TL, Cronin-Fenton DP. Glucocorticoid prescriptions and breast cancer recurrence: A Danish nationwide prospective cohort study. Ann Oncol. 2014;25(12):2419-25. PMCID: PMC4239807.
- 23. Cronin-Fenton DP, Heide-Jørgensen U, **Ahern TP**, Lash TL, Christiansen PM, Ejlertsen B, Sjøren P, Kehlet H, Sørensen HT. Opioids and breast cancer recurrence: A Danish population-based cohort study. Cancer. 2015;121(19):3507-14 PMCID: PMC4575607.
- 24. Cronin-Fenton DP, Sørensen HT, Ejlertsen B, Christiansen PM, Ahern TP, Lash TL, Heide-Jørgensen U. Low-dose aspirin, non-steroidal anti-inflammatory drugs, selective COX-2 inhibitors and breast cancer recurrence. Epidemiology. 2016 2016;27(4):586-93. PMCID: PMC5541136.
- 25. Borgquist S, Tamimi RM, Chen WY, Garber JE, Eliassen AH, **Ahern TP**. Statins and breast cancer risk in the Nurses' Health Study. Cancer Epidemiol Biomarkers Prev. 2016;25(1):201-6. PMCID: PMC4842011.
- 26. **Ahern TP,** Cronin-Fenton DP, Lash TL, Sørensen HT, Ording AO, Hamilton-Dutoit SJ. Helberg Y. Pak1, adjuvant tamoxifen therapy, and breast cancer recurrence risk in a Danish population-based study. Acta Oncol. 2016;55(6):734-41. PMCID: PMC4943575.
- 27. **Ahern TP**, Hertz DL, Damkier P, Ejlertsen B, Hamilton-Dutoit SJ, Rae JM, Regan MM, Thompson AM, Lash TL, Cronin-Fenton DP. Cytochrome P-450 2D6 (CYP2D6) genotype and breast cancer recurrence in tamoxifen-treated patients: evaluating the importance of loss-of-heterozygosity. Am J Epidemiol. 2017;185(2):75-85. PMCID: PMC5253974.
- 28. **Ahern TP**, Beck AH, Rosner BA, Glass B, Frieling G, Collins LC, Tamimi RM. Continuous measurement of breast tumor hormone receptor expression: a comparison of two computational pathology platforms. J Clin Pathol. 2017;70:428-34. PMCID: PMC5763511.
- 29. Lash TL, Riis AH, Ostenfeld EB, Erichsen R, Vyberg M, **Ahern TP**, Thorlacius- Ussing O. Associations of Statin Use With Colorectal Cancer Recurrence and Mortality in a Danish Cohort. Am J Epidemiol. 2017 Sep 15;186(6):679-687. PMID: 28338891
- 30. Borgquist S, Giobbie-Hurder A, **Ahern TP**, Garber J, Colleoni M, Lang I, Debled M, Ejlertsen B, von Moos R, Smith I, Coates A, Goldhirsch A, Rabaglio M, Price K, Gelber R, Regan M, Thuerlimann B. Cholesterol, Cholesterol-Lowering Medication Use, and Breast Cancer Outcome in the BIG 1-98 Study. J Clin Oncol. 2017;35(11):1179-90.
- 31. Broe A, Ennis ZN, Pottegård A, Hallas J, **Ahern TP**, Damkier P. Population Exposure to Phthalate-Containing Drugs. Basic Clin Pharmacol Toxicol. Sep;121(3):153-158.2017 PMID: 28371296
- 32. Ahern TP, Sprague BL, Bissell MCS, Miglioretti DL, Buist DSM, Braithwaite D,

Kerlikowske K. Family history of breast cancer, breast density, and breast cancer risk in a U.S. breast cancer screening population. Cancer Epidemiol Biomarkers Prev. 2017;26(6):938-44. PMCID: PMC5457358.

- 33. Cronin-Fenton DP, Kjærsgaard A, **Ahern TP**, Mele M, Ewertz M, Hamilton-Dutoit S, Christiansen P, Ejlertsen B, Sørensen HT, Lash TL, Silliman RA. Validity of Danish Breast Cancer Group (DBCG) registry data used in the Predictors of Breast Cancer Recurrence (ProBeCaRe) premenopausal breast cancer cohort study. Acta Oncol. Sep;56(9):1155-1160 2017.
- 34. Klebaner D, Hamilton-Dutoit S, **Ahern T**, Crawford A, Jakobsen T, Cronin-Fenton DP, Damkier P, Janssen E, Kjaersgaard A, Ording AG, Søiland H, Sorensen HT, Lash TL, Hellberg Y. Apolipoprotein D expression does not predict breast cancer recurrence among tamoxifen-treated patients. PLoS One. 2017;12(3):e0171453. PMCID: PMC5354362.
- 35. Damkier P, Kjaersgaard A, Barker KA, Cronin-Fenton DP, Crawford A, Hellberg Y, Janssen EAM, Langefeld C, **Ahern TP**, Lash TL. CYP2C19\*2 and CYP2C19\*17 variants and effect of tamoxifen on breast cancer recurrence: Analysis of the International Tamoxifen Pharmacogenomics Consortium dataset. Sci Reports 2017;7(1):7727. PMCID: PMC5552748.
- 36. Farina NH, Ramsey JE, Sands ME, **Ahern TP**, Shirley DJ, Stein JL, Stein GS, Lian JB, Wood ME. Development of a predictive miRNA signature for breast cancer risk among high-risk women. Oncotarget. 2017;8(68):112170-112183. PMCID: PMC5762501.
- 37. Broe A, Pottegård A, Hallas J, **Ahern TP**, Fedder J, Damkier P. Association between use of phthalate-containing medication and semen quality among men in couples referred for assisted reproduction. Hum Reprod. 2018 [Epub ahead of print] PMID: 29425332
- 38. Ennis ZN, Broe A, Pottegård A, **Ahern TP**, Hallas J, Damkier P. Cumulative exposure to phthalates from phthalate-containing drug products: a Danish population-wide study. British J Clin Pharmacol. 2018;84(8):1798-1805. PMCID: PMC6046487
- 39. Fujii MH, Hodges AC, Russell RL, Roensch K, Beynnon B, **Ahern TP**, Holoch P, Moore JS, Ames SE, MacLean CD. Post-discharge opioid prescribing and use following common surgical procedures. J Am Coll Surg. 2018;226(6):1004-12 PMCID: PMC5971152
- 40. **Ahern TP**, Veres K, Jiang T, Farkas DK, Lash TL, Sørensen HT, Gradus JL. Adjustment disorder and type-specific cancer incidence: a Danish cohort study. Acta Oncol. 2018 [Epub ahead of print] PMID: 29688114
- 41. Pottegård A, Lash TL, Cronin-Fenton DP, Ahern TP, Damkier P. Use of antipsychotics and risk of breast cancer: a Danish nationwide case-control study. Br J Clin Pharmacol. 2018;84(9):2152-61 PMID: 29858518
- 42. Collin LJ, Cronin-Fenton DP, **Ahern TP**, Christensen KB, Damkier P, Hamilton-Dutoit S, Kjaersgaard A, Lauridsen KL, Yacoub R, Christiansen P, Sørensen HT, Lash TL. Expression of survivin does not appear to influence breast cancer recurrence risk. Acta Oncol. 2018 [In press]
- 43. Colton I, Fujii M, **Ahern TP**, MacLean C, Lahiri J, Alef M, Stanley A, Steinthorsson G, Bertges D. Postoperative Opioid Prescriving Patterns and Use after Vascular Surgery. *Vasc Med.* [In press]
- 44. Collin LJ, Cronin-Fenton DP, **Ahern TP**, Christiansen PM, Damkier P, Ejlertsen B, Hamilton-Dutoit S, Kjærsgaard A, Silliman RA, Sørensen HT, Lash TL. Cohort Profile: the Predictors of Breast Cancer Recurrence (ProBe CaRe) Premenopausal Breast Cancer Cohort Study in Denmark. BMJ Open. 2018;8(7):e021805. PMID: 30068618 PMCID: PMC6074634.

45. Paine AN, Krompf BL, Borrazzo EC, **Ahern TP**, Malhotra AK, Norotsky MC, Tsai MH. The Impact of an Acute Care Surgery Model on General Surgery Service Productivity. Periperative Care and Operating Room Management. 2018;[In press]

#### In Review

1. **Ahern TP**, Broe A, Lash TL, Cronin-Fenton DP, Ulrichsen SP, Christiansen PM, Cole BF, Tamimi RM, Sørensen HT, Damkier P. Phthalate exposure and breast cancer incidence: a Danish nationwide cohort study.

#### In Preparation

1. **Ahern TP**, Damkier P, Kjaersgaard A, Sørensen HT, Hamilton-Dutoit S, Ejlertsen B, Christiansen P, Silliman RA, Lash TL, Cronin-Fenton DP. Impact of co-medications on tamoxifen effectiveness in premenopausal breast cancer patients: a study from the Danish population-based ProBe CaRe cohort.

#### **Review Articles**

- 1. **Ahern TP**, Lash TL, Damkier P, Christiansen PM, Cronin-Fenton DP. Statins and breast cancer prognosis: evidence and opportunities. Lancet Oncol. 2014;15:e461-8. PMCID: PMC4167822.
- 2. Borgquist S, Bjarnadottir O, Kimbung S, **Ahern TP**. Statins: a role in breast cancer therapy? J Intern Med. 2018;284(4):346-57. PMID: 29923256

#### **Books and Chapters**

1. **Ahern TP**. Pharmacoepidemiology in Pharmacogenetics. In: Advances in Pharmacology, volume 83. Damkier P and Brøsen K (eds.)

#### **Non-Peer Reviewed Publications**

#### Letters

- 1. Lash TL, **Ahern TP**, Cronin-Fenton D, Garne JP, Hamilton-Dutoit S, Sørensen HT. Comment on 'Impact of CYP2D6\*10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy'. Cancer Sci 2008;99:1706-7.
- 2. Lash TL, **Ahern TP**, Cronin-Fenton D. Modification of tamoxifen response: what have we learned? J Clin Oncol 2008;26:1764-5; author reply 1765-6.
- 3. **Ahern TP,** Hankinson SE. Re: Use of Archived Specimens in Evaluation of Prognostic and Predictive Biomarkers. J Natl Cancer Inst 2011;103:1558-9.
- 4. Sørensen GV, Cronin-Fenton DP, Sørensen HT, Damkier P, Ejlertsen B, Christiansen PM, Lash TL, **Ahern TP**. Re: Beta blockers and improved progression-free survival in patients with advanced HER2 negative breast cancer. Epidemiology. 2018 [Epub ahead of print] PMID: 29771735
- 5. **Ahern TP**, Borgquist S, Cronin-Fenton DP. Re: Association of statin use with overall and cancer survival. JAMA Oncol. 2018;4(7)1015-16 PMID: 29800042

#### Thesis

1. Ahern TP. Estimating the Impact of Molecular Profiles and Prescription Drugs on Breast Cancer Outcomes [dissertation]. Boston (MA): Boston University; 2010.

#### **Abstracts**

#### **Patents Issued or Pending**

# **Other Creative Activities**

# **Quality Improvement and Patient Safety Activities**

# SUMMARY OF SCHOLARLY ACTIVITIES

aaa

# **INVITED PRESENTATIONS**

Regional		
<b>Years</b>	Host Organization	City, State
2008	Boston University School of Public Health,	Boston, MA
	Research in Progress Seminar; Department of	
	Epidemiology. "Cardiac Glycosides and Breast	
	Cancer."	
2011	Channing Laboratory, Brigham and Women's	Boston, MA
	Hospital and Harvard Medical School. "Associations	
	of Plasma Insulin and C-peptide Levels with	
	Mammographic Breast Density and Breast Cancer	
2011	Risk	D / MA
2011	Harvard School of Public Health Department of	Boston, MA
	Epidemiology, Cancer Epidemiology Fellows'	
	Meeting. "Statin Use and Breast Cancer Recurrence: A Danish Nationwide Prospective Cohort Study."	
2011	Dana-Farber/Harvard Cancer Center Programs in	Boston, MA
2011	Breast and Gynecologic Cancer, Joint Symposium.	Doston, WIT
	"Estimating the Association between Vitamin K	
	Antagonist Therapy and Site-Specific Cancer	
	Incidence Using Heart Valve Replacement as an	
	Instrumental Variable."	
2012	Channing Laboratory, Brigham and Women's	Boston, MA
	Hospital and Harvard Medical School, Molecular	
	Pathology Working Group Seminar. "Quantitative	
	Measurement of Breast Tumor Biomarkers in the	
	Nurses' Health Study."	
2013	University of Vermont College of Medicine	Burlington, VT
	Department of Pharmacology Seminar.	
	"Pharmacoepidemiology studies using the Danish	
	national health registries: examples and opportunities."	
2014	University of Vermont, Vermont Cancer Center,	Burlington, VT
2014	Cancer Control and Population Health Sciences	Durinigion, VI
	Program Meeting. "Validation linked with	
	probabilistic bias analysis in a study of	
	anticoagulants and cancer incidence."	
2014	Vermont Breast Cancer Conference (Keynote	Burlington, VT
	Address). "Looking for Avoidable Causes of Breast	ξ,
	Cancer: No Trivial Pursuit!"	
2014	Vermont Breast Cancer Conference. "Phthalates are	Burlington, VT

6/7/2018 2016	Everywhere—But Do They Cause Breast Cancer?" University of Vermont Larner College of Medicine Department of Biochemistry, Cancer Research and Technology Seminar. "Molecular Mechanisms of Tamoxifen Resistance."	Thomas Patrick Ahern Burlington, VT
National Years 2011	Host Organization  American Association for Cancer Research; Annual Meeting, "Post-diagnosis use of lipophilic statins and breast cancer recurrence: A Danish nationwide	<u>City, State</u> Orlando, FL
2011	cohort study." Poster presentation. Congressionally Directed Medical Research Programs; Era of Hope Meeting, "Functional polymorphisms in UDP-glucuronosyl transferases and recurrence in tamoxifen-treated breast cancer	Orlando, FL
2011	survivors." Poster presentation.  American Association for Cancer Research;  Frontiers in Cancer Prevention Research, "C- peptide, mammographic density, and risk of invasive	Boston, MA
2014	breast cancer." Poster presentation.  American Association for Cancer Research;  Frontiers in Cancer Prevention Research, "Digoxin use and risk of invasive breast cancer: evidence from the Nurses' Health Study." Poster presentation.	National Harbor, MD
2014	Society for Epidemiologic Research; Annual Meeting, "Breast tumor Pak1 expression, adjuvant tamoxifen therapy, and recurrence risk: a Danish population-based study." Poster presentation.	Seattle, WA
2014	Society for Epidemiologic Research; Annual Meeting, "Vitamin K antagonist drugs and cancer risk: validation of heart valve replacement as a drug exposure proxy." Invited talk.	Seattle, WA
2015	Departmental Research Seminar; Department of Epidemiology and Biostatistics, University of Massachusetts, "How to Do Environmental Epidemiology If You Are Locked in a Pharmacy: Drugs, Phthalates, and Breast Cancer Risk." Invited talk.	Amherst, MA
2015	Northeastern Breast Cancer Research Conference, Norris Cotton Cancer Center, Dartmouth University, "Breast Cancer Pharmacoepidemiology in the Danish National Cohort." Invited talk.	Lebanon, NH
2015	San Antonio Breast Cancer Symposium, "Statins and breast cancer risk in the Nurses' Health Study." Platform and poster discussion.	San Antonio, TX
2015	San Antonio Breast Cancer Symposium, "CYP2D6 genotype and breast cancer recurrence in tamoxifen treated patients: an evaluation of the importance of	San Antonio, TX

6/7/2018		Thomas Patrick Ahern
2016	loss-of-heterozygosity." Poster presentation. Society for Epidemiologic Research, Annual Meeting, "Continuous measurement of breast tumor hormone receptor expression: a comparison of two computational pathology platforms." Poster	Miami, FL
2017	presentation. Society for Epidemiologic Research, Annual Meeting, "Drug interactions with tamoxifen in a Danish premenopausal breast cancer cohort." Invited talk.	Seattle, WA
2018	Society for Epidemiologic Research, Annual Meeting, "Bayesian meta-analysis and visual examination of assumptions via an online app." Invited talk.	Baltimore, MD
2018	Society for Epidemiologic Research, Annual Meeting, "Breast cancer risk in chronic users of phthalate-containing medications: A Danish	Baltimore, MD
2018	nationwide cohort study." Poster presentation. Emory University/Winship Cancer Institute Cancer Control and Population Health Sciences Grand Rounds. "Breast cancer risk in users of phthalate-containing medications: A Danish nationwide cohort study"	Atlanta, GA
International	incured one. It builds nation wide conort stady	
Years	Host Organization	City, Country
2010	Aarhus University Hospital Department of Clinical Epidemiology, "The potential role of p21-activated kinase 1 in tamoxifen resistance.	Aarhus, Denmark
2013	University of South Denmark Department of Clinical Biochemistry and Pharmacology, "Breast cancer risk in chronic users of phthalate-containing medications."	Odense, Denmark
2014	SOLA Investigators' Meeting, "Predictive biomarkers of simvastatin effectiveness in the breast cancer adjuvant setting." Invited talk.	Stavanger, Norway
2017	Lund University, "Statins and breast cancer: current evidence and potential pathways." Invited talk.	Lund, Sweden
2017	International Conference on Pharmacoepidemiology and Therapeutic Risk Management, "Drug interactions with tamoxifen in a Danish	Montréal, Canada
	premenopausal breast cancer cohort." Spotlight	
2018	premenopausal breast cancer cohort." Spotlight poster presentation. International Conference on Pharmacoepidemiology and Therapeutic Risk Management, "Breast cancer risk in chronic users of phthalate-containing medications: a Danish nationwide cohort study." Invited talk.	Prague, Czech Republic

poster presentation.